Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA
LOS ANGELES--(BUSINESS WIRE)--Mar 3, 2025--
Laekna (2105.HK) announced that the U.S. Food and Drug Administration (FDA) has approved the IND for LAE120, an internally discovered USP1 inhibitor, for the treatment of advanced solid tumors.
This press release features multimedia. View the full release here:
Laekna (2105.HK) announced that the FDA has approved the IND for LAE120, an internally discovered USP1 inhibitor, for the treatment of advanced solid tumors. (Photo: Business Wire)
LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor in HRD (homologous recombination deficiency) cancers. It has a unique chemical structure differentiated from all the other disclosed USP1 inhibitors and is expected to induce a different conformational change in USP1. LAE120 shows robust tumor inhibitory activity across various xenograft models such as MDA-MB-436 and K562 as a single agent and exhibits synergistic effect in combination with PARP inhibitors. It also demonstrates good therapeutic windows in GLP long-term toxicology study. Laekna is actively exploring partnerships to accelerate the clinical development of LAE120.
'Leveraging our deep know-how and extensive expertise in drug discovery, Laekna has developed a distinctive portfolio of innovative drug candidates through the close collaboration of our Med Chem, Biology and AIDD (AI-driven Drug Discovery) teams, continuously advancing preclinical drug candidates into clinical stage. Laekna has also significantly accelerated the progress of drug discovery by utilizing cutting-edge artificial intelligence tools,' said Dr. Justin Gu, Chief Scientific Officer of Laekna. 'We look forward to bringing novel drugs to patients as swiftly as possible,' he added.
Advancing Diversified Pipelines
Laekna is actively advancing preclinical drug candidates. In the fourth quarter of 2024, another internally discovered anti-tumor drug candidate, LAE118, a potentially best-in-class, mutant-selective PI3Kαinhibitor, has advanced to IND-enabling study. PI3Kα mutations are prevalent in patients with breast, colorectal, lung, endometrial, and numerous other cancers. However, the first-generation drugs targeting PI3Kα inhibit the wild-type and mutant PI3Kα with equal potency, which raises concerns of tolerability and therapeutic efficacy.
As a novel allosteric inhibitor, LAE118 demonstrates excellent potency and selectivity towards various PI3Kα mutants. With superior anti-cancer efficacy and tolerability than other current PI3Kα inhibitors, LAE118 is potentially the best-in-class pan-mutant-selective PI3Kα inhibitor. Laekna has presented the preclinical characterization of LAE118 at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. LAE118 is in IND-enabling studies and IND is expected to be filed in the fourth quarter of 2025.
Strategic Partnerships to Accelerate Globalization
'We will continue to advance and expand our product portfolio in the therapeutic areas where we have accumulated tremendous experience and extensive know-how,' said Dr. Chris Lu, Chief Executive Officer of Laekna. 'In November 2024, the Group has entered into a clinical collaboration agreement with Lilly (NYSE:LLY) to support and accelerate global clinical development of LAE102 for the treatment of obesity. We plan to pursue strategic partnerships with global leading pharmaceutical companies to accelerate clinical development and commercialization of our drug candidate assets. We keep advancing and expanding our pipeline and are committed to bringing life-changing medicines to more people around the world,' he added.
About Laekna
Stock Code: 2105.HK
Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapeutics to patients with cancer, metabolic diseases and liver fibrosis patients around the world.
As of June 30, 2024, Laekna has initiated seven clinical trials for LAE102, LAE002(afuresertib), LAE001 and LAE005 to address unmet medical needs in obesity and cancers.
LAE102 is our internally discovered antibody against ActRIIA. It has been shown in the pre-clinical studies to increase lean mass and decrease fat mass. We've obtained IND approvals from the FDA and the CDE for LAE102 in obesity indication and are advancing the Phase I clinical trial in China.
Blocking Activin-ActRII pathway could promote muscle regeneration and decrease fat mass. Laekna team has accumulated tremendous experiences and deep know-how in this specific field and is developing more drug candidates (LAE103 and LAE123), in addition to LAE102, to maximize the value of targeting ActRII receptors.
In the cancer area, Laekna has built a comprehensive portfolio of drug candidates, covering the treatment of breast cancer, prostate cancer, ovarian cancer and PD-1/ PD-L1 drug-resistant solid tumors. LAE002 (afuresertib) is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the only two AKT inhibitors in late-stage development for breast and prostate cancer globally. Laekna has commenced the Phase III clinical trial (AFFIRM-205) for LAE002 in patients with HR+/HER2- breast cancer.
Laekna, Inc. (2105.HK) was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the 'Hong Kong Stock Exchange') on June 29, 2023.
Forward-Looking Statements
This press release may contain certain 'forward-looking statements' which are not historical facts, but instead are predictions about future events based on Laekna's current beliefs, assumptions and expectations, commonly identified by words such as 'would', 'may', 'expects', 'believes', 'plans', 'intends', 'projects' and other terms with similar meaning. Although we believe that our predictions are reasonable, future events are inherently uncertain and our actual future results or performance may be materially different from what we expect. Accordingly, you are strongly cautioned that reliance on any forward-looking statements is subject to significant known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.
SOURCE: Laekna
Copyright Business Wire 2025.
PUB: 03/03/2025 09:30 PM/DISC: 03/03/2025 09:29 PM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Breakthrough procedure helps prevent amputations for Sacramento area patients
( — A breakthrough surgery helping save limbs and lives took place in Sacramento on Wednesday morning. The procedure aims to treat people suffering from Peripheral Artery Disease. PAD is a serious and rarely-treated circulatory condition that restricts blood flow to the limbs due to narrowed blood vessels. It kills more people than breast, colon, and prostate cancer combined. 'Plaque that builds up in these arteries causes not only hardening of the arteries but also plaque in these blood vessels,' said Dr. Inder Singh, an interventional cardiovascular specialist at TLC Vascular. When blood can't flow properly, minor wounds can become dangerous. They can lead to infection and, in some cases, amputation. Michaels Distributing Center in San Joaquin County set to close, affecting over 200 jobs 'If they get an injury or they get a wound or they get a scratch, those will not heal because they don't have enough, adequate perfusion to heal those wounds,' Dr. Singh said. Helping to change patient outcomes, Dr. Singh is now performing a first-of-its-kind procedure using a newly FDA-cleared removable stent called SPUR. 'The idea with it is that basically that kind of treatment that deep penetrates into the tissue and treats it, it will prevent future closure or at least prolong the time from when the blood vessels close,' said Dr. Singh. 'Enabling the patients to be able to heal their wounds, which is really the main outcome we're looking for.' is the first in the Sacramento area to use SPUR, designed specifically for the small, fragile arteries below the knee. Unlike a traditional stent, the spur temporarily holds the vessel open and then is removed, leaving nothing behind. Charges filed against former Cal Fire employee in child pornography case 'We can see somebody on an outpatient basis one day and actually fix a problem rather than put a band-aid on, you know, the incorrect problem,' said Shelby Adney, a nurse practitioner at TLC Vascular. It's an innovative procedure now preventing amputations, healing wounds, and maintaining patients' normal lives. 'Once you can preserve that and heal their wounds… they get their life back,' Dr. Singh said. 'They're ambulatory. They can spend time with their family. You can do a lot of things that most people expect to do.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
‘Drugs alone not the answer', says top GP as he talks about weight loss jabs
A leading GP and TV medic has told fitness industry professionals gathered in Bolton that drugs alone are not the way to fight obesity. Dr Hussain Al-Zubaidi, a regular guest on Channel 4's "Steph's Packed Lunch" and the lifestyle and physical activity lead for the Royal College of General Practitioners, shared this sentiment at a professional development event for the health, fitness, and wellbeing sector. He was addressing the professionals, at the Bolton Arena Community Sports Village, on the roll-out of GLP-1 drugs, sometimes referred to colloquially as fat jabs or fat pills. These medicines, which can be taken as tablets or injections, are used to treat type 2 diabetes and can aid weight loss by reducing a patient's appetite. Dr Al-Zubaidi said: "The roll-out of GLP-1s within primary care is very much the hot topic at the moment. "It is going to transform how we deliver primary care – and a lot of other things. "As we roll out GLP-1 therapies in primary care, we must resist the temptation to settle for the minimal scalable model of lifestyle support. "I was emphasising that people deserve better than that. "Our patients deserve a comprehensive, multi-component approach – nutrition, behavioural and psychological support, sleep and stress management, physical activity, and addiction care all working in harmony." His remarks come during an ongoing debate within the fitness sector about the role of GLP-1s in addressing obesity. The event was hosted by the LFX network in partnership with GM Active, a group made up of 12 leisure and community organisations – including Bolton Arena – that manage most publicly owned leisure and physical activity facilities on behalf of the 10 authorities across Greater Manchester. GM Active chair, Andy King, said: "It's not often a 'moment in time' occurs that you know will be considered a 'turning point' in the future, yet this event will be one of those, I am sure. "Thanks to the LFX network, GM Active is set fair to really understand how we can support those people who, through one way or another, have opted to utilise these tools to assist them to lose weight and help them to sustain their gains for the longer term through pragmatic and people-centred, wrap-around support." READ MORE: Bolton charity boss honoured with invite to Palace garden party Three Bolton businesses named for not paying minimum wage 'Top local chippy' nominated for award - cast your vote Dr Al-Zubaidi added: "The fitness professionals in that packed room have shown they're ready to play their part – now it's time for all of us to turn that eagerness into action." Neil Hutchinson, managing director of Bolton Arena Community Sports Village, said: "We've been working on a new health and wellbeing strategy for Bolton over the last six months, so I was keen to host this event and be at the front of this discussion. "We aim to be on the front foot with this in Bolton and ready to support local GPs and primary care in this revolutionary healthcare development."
Yahoo
5 hours ago
- Yahoo
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@
